AZD 1080

Drug Profile

AZD 1080

Alternative Names: AZD1080

Latest Information Update: 12 Feb 2008

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antidementias
  • Mechanism of Action Glycogen synthase kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 12 Feb 2008 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (unspecified route)
  • 06 Aug 2004 Preclinical trials in Alzheimer's disease in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top